<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206281</article-id><article-id pub-id-type="doi">10.1101/2025.06.06.658274</article-id><article-id pub-id-type="archive">PPR1032194</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>LIMD1 Loss Confers a GPX4-Dependent Cell State in Lung Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saha</surname><given-names>Akash</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grevitt</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">##</xref></contrib><contrib contrib-type="author"><name><surname>Junior</surname><given-names>Jair Marques</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Von Kriegsheim</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Kunal</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stockwell</surname><given-names>Brent R.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Finch</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Peck</surname><given-names>Barrie</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sharp</surname><given-names>Tyson V.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR2">#</xref></contrib></contrib-group><aff id="A1"><label>1</label>Centre for Cancer Cell &amp; Molecular Biology, Barts Cancer Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>Queen Mary University of London</institution></institution-wrap>, <addr-line>Charterhouse Square</addr-line>, <city>London</city>, <postal-code>EC1M 6BQ</postal-code>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a7t9b67</institution-id><institution>Cancer Research UK Edinburgh Centre</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05hygey35</institution-id><institution>Institute of Genetics and Cancer</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>University of Edinburgh</institution></institution-wrap>, <addr-line>Crewe Road</addr-line>, <city>Edinburgh</city><postal-code>EH4 2XR</postal-code>, <country country="GB">UK</country></aff><aff id="A3"><label>3</label>Department of Biological Sciences, Department of Chemistry, Department of Pathology and Cell Biology, Data Science Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/051kc1939</institution-id><institution>Herbert Irving Comprehensive Cancer Centre</institution></institution-wrap>, Irving Institute for Cancer Dynamics, Digestive and Liver Disease Research Centre, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj8s172</institution-id><institution>Columbia University</institution></institution-wrap>, <city>New York</city>, <state>NY</state>, <country country="US">USA</country></aff><aff id="A4"><label>4</label>Centre for Tumour Biology, Barts Cancer Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>Queen Mary University of London</institution></institution-wrap>, <addr-line>Charterhouse Square</addr-line>, <city>London</city>, <postal-code>EC1M 6BQ</postal-code>, <country country="GB">UK</country></aff><author-notes><corresp id="CR1">
<label>##</label>Co-corresponding Author: Paul Grevitt; <email>p.grevitt@qmul.ac.uk</email></corresp><corresp id="CR2">
<label>#</label>Corresponding Author: Prof Tyson V. Sharp; <email>t.sharp@qmul.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>08</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>07</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1"><italic>LIMD1</italic> (LIM domains containing 1) is a bona-fide tumour suppressor gene frequently lost during the early stages of non-small cell lung cancer (NSCLC) development, resulting in a worse outcome for <italic>LIMD1</italic>-deficient patients. <italic>LIMD1</italic> deficiency is present in approximately 50% of NSCLC cases, representing at least 21,000 patients in the United Kingdom and 1.2 million worldwide. During cancer progression, cells can accumulate genetic changes that render them more dependent on certain genes for their survival. By performing CRISPR-Cas9 dropout screens, we identified <italic>GPX4</italic> as a novel vulnerability in <italic>LIMD1</italic> deficient LUAD cells. By targeting <italic>GPX4</italic> using RNA interference (RNAi) and pharmacological intervention in our isogenic LUAD lines along with a non-transformed lung cell line, we validated GPX4 as a novel dependency in <italic>LIMD1</italic> deficient cells. GPX4 is a key defence mechanism against ferroptosis, an iron-dependent form of regulated cell death. This state of increased ferroptosis susceptibility upon <italic>LIMD1</italic> loss is due to increased basal reactive oxygen species levels and lipid peroxidation. Importantly, targeting GPX4 with ferroptosis inducing agents in NSCLC patients with <italic>LIMD1</italic> loss may represent a novel therapeutic strategy.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Lung cancer (LC) remains the leading cause of cancer-related morbidity and mortality globally, with approximately 2 million new cases and 1.8 million deaths each year <sup><xref ref-type="bibr" rid="R1">1</xref></sup>. In the UK, LC is the third most common cause of cancer-related death, accounting for 21% of all cancer fatalities and over 34,800 deaths annually <sup><xref ref-type="bibr" rid="R2">2</xref></sup>. It also ranks as the third most frequently diagnosed cancer in the UK, with more than 48,500 new cases annually <sup><xref ref-type="bibr" rid="R2">2</xref></sup>. LC is broadly classified into small-cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), constituting 15% and 85% of cases, respectively <sup><xref ref-type="bibr" rid="R3">3</xref></sup>. NSCLC is further subdivided into large-cell carcinoma, lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC), with LUAD and LUSC representing 40% and 25-30% of all LC cases <sup><xref ref-type="bibr" rid="R4">4</xref></sup>.</p><p id="P3">Disease stage at diagnosis is the most critical determinant of patient prognosis and therapeutic options <sup><xref ref-type="bibr" rid="R5">5</xref></sup>. Early-stage NSCLC (stages I-II) is typically treated with surgical resection, offering 5-year survival rates of 64.6% and 41.2%, respectively <sup><xref ref-type="bibr" rid="R6">6</xref></sup>. In contrast, advanced-stage NSCLC (stages III-IV) has significantly poorer 5-year survival outcomes of 36-13% and 1%, respectively <sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup>. Treatment for advanced disease often includes chemotherapy and radiation, but outcomes remain dismal <sup><xref ref-type="bibr" rid="R1">1</xref></sup>. A key challenge in LC management is the high frequency of late diagnosis due to symptom overlap with other chronic respiratory diseases, resulting in more than 60% of patients presenting with advanced-stage diseases <sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Despite recent advances in immunotherapy and tyrosine kinase inhibitors (TKIs), overall 5-year survival rates remain stagnant at 18% <sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup>, underscoring the urgent need for novel, personalised treatment approaches.</p><p id="P4">LIM domain-containing protein 1 gene (LIMD1), a 73 kDa tumour suppressor encoded within the common eliminated region 1 (C3CER1) on chromosome 3p21.3, plays a critical role in LC tumorigenesis <sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>. Deletions in this region are frequent across multiple cancers, including breast, colorectal ovarian, renal, and gastric malignancies <sup><xref ref-type="bibr" rid="R14">14</xref></sup>. LIMD1 is subject to both genomic deletion and epigenetic silencing via promoter hypermethylation, which represses transcriptional activity <sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup>. Importantly, LIMD1 loss occurs early in NSCLC development: approximately 46% of LUAD and 85% of LUSC patients exhibit monoallelic deletion, with TRACERx data indicating this loss is often clonal <sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>. Copy number correlates strongly with mRNA expression levels in both LUAD and LUSC, and patients with LIMD1 loss show reduced expression <sup><xref ref-type="bibr" rid="R16">16</xref></sup>. TCGA data further confirm significantly lower LIMD1 mRNA expression in tumour samples compared to adjacent normal tissue, which is associated with worse prognosis in LUAD <sup><xref ref-type="bibr" rid="R16">16</xref></sup>.</p><p id="P5">It has been robustly demonstrated that LIMD1 loss drives NSCLC progression <sup><italic>18</italic></sup>. LIMD1 overexpression in LUAD cell lines suppresses colony formation, indicating a growth-suppressive role <sup><xref ref-type="bibr" rid="R18">18</xref></sup>. <italic>In vivo, Limd1</italic><sup>-/-</sup> mice develop significantly more and larger lung tumours upon urethane exposure or in the <italic>KRAS</italic><sup><italic>G12D</italic></sup> background <sup><xref ref-type="bibr" rid="R12">12</xref></sup>.</p><p id="P6">LIMD1 is a member of the Zyxin family of LIM domain containing proteins, characterised by an unstructured N-terminal pre-LIM domain and three tandem zinc-finger LIM domains at the C-terminus, facilitating protein-protein interactions <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. LIM domains are evolutionarily conserved modules that regulate diverse processes, including gene expression, signalling, and cell adhesion <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. As a multifunctional scaffold, LIMD1 integrates signals across multiple homeostatic pathways <sup><xref ref-type="bibr" rid="R20">20</xref></sup>. Notably, LIMD1 binds the retinoblastoma protein (pRb), suppressing E2F1-driven transcription and, cell cycle progression <sup><xref ref-type="bibr" rid="R18">18</xref></sup>. It also modulates the hypoxic response by promoting efficient hydroxylation and proteasomal degradation of HIF -1α via scaffolding and recruiting a PHD-pVHL complex <sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>. More recently, LIMD1 was shown to be important for microRNA-induced silencing complex (miRISC) function through site-specific phosphorylation <sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref></sup>.</p><p id="P7">Given its pleiotropic regulatory roles, LIMD1 loss disrupts multiple tumour-suppressive pathways, promoting tumour initiation, progression, and metastasis <sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>. However, the multi-faceted nature of LIMD1 biology complicates direct therapeutic targeting. A prior drug repurposing screen identified PF-477736 as selectively cytotoxic to <italic>LIMD1</italic>-deficient NSCLC cells <sup><xref ref-type="bibr" rid="R20">20</xref></sup>. Although originally designed as a Chk1 inhibitor, its mechanism of action was independent of Chk1, functioning instead as a broad-spectrum kinase inhibitor <sup><xref ref-type="bibr" rid="R20">20</xref></sup>. Despite showing <italic>in vitro</italic> and <italic>in vivo</italic> efficacy, the undefined mechanism limits clinical translation, highlighting the need for better LIMD1 targeted strategies.</p><p id="P8">Given the early and frequent loss of <italic>LIMD1</italic> in NSCLC, synthetic lethality offers a promising route to selectively target <italic>LIMD1</italic>-deficient tumours. Synthetic lethality arises when simultaneous disruption of two genes leads to cell death, whereas loss of either alone is tolerated <sup><xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R25">25</xref></sup>. This approach enables targeted elimination of tumour cells harbouring specific vulnerabilities, sparing normal cells.</p><p id="P9">To identify such vulnerabilities, we conducted genome-wide CRISPR-Cas9 dropout screens in isogenic <italic>LIMD1</italic><sup><italic>+/+</italic></sup> and <italic>LIMD1</italic><sup>-/-</sup>cells. This revealed a dependency in <italic>LIMD1</italic>-deficient cells on components of the selenocysteine biosynthesis and incorporation pathway – including EEFSEC, SEPSECS, and PSTK – and critically, on the selenoprotein GPX4. GPX4 is a key antioxidant enzyme that prevents ferroptosis, an iron-dependent form of regulated cell death triggered by uncontrolled lipid peroxidation in polyunsaturated phospholipids <sup><xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R28">28</xref></sup>.</p><p id="P10">Here, we functionally validate GPX4 as a synthetic lethal target in <italic>LIMD1</italic>-deficient cells using both siRNA-mediated knockdown and pharmacological inhibition. Our results across LUAD cell lines and isogenic small airway epithelial cells (SAECs) demonstrate a clear and selective vulnerability, positioning GPX4 as a promising therapeutic target for a genomically defined NSCLC subset.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S3"><title>Cell lines and culture conditions</title><p id="P11">A549 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco), while H1299 cells were maintained in Roswell Park Memorial Institute 1640 Medium (RPMI 1640; Gibco) or Plasmax (Ximbio, #156371). SAECs were cultured using Promocell Small Airway Epithelial Cell Basal Medium (PromoCell; C-21270), supplemented with the provided Supplement mix (PromoCell; C-39170). All culture media were supplemented with 10% (v/v) fetal bovine serum (FBS; Sigma-Aldrich) and 1% (v/v) penicillin-streptomycin (ThermoFisher Scientific). Cells were incubated at 37 °C, with 5% CO<sub>2</sub> and passaged at 80% confluency. Mycoplasma testing was routinely performed, and cells were used up to passage 10. Cell numbers were quantified using a Countess II automated cell counter (ThermoFisher Scientific) to ensure optimal seeding density for each assay.</p></sec><sec id="S4"><title>CRISPR-Cas9 dropout screen</title><p id="P12">HEK293T cells were transfected with Cas9 endonuclease to generate viral particles for subsequent transduction of isogenic <italic>LIMD1</italic><sup>+/+</sup> and <italic>LIMD1</italic><sup>-/-</sup> A549 cells. The Human Improved Genome-Wide Knockout CRISPR Library v1 (Addgene #67989), containing 90,709 guide sequences targeting a total of 18,010 genes, was cloned into a lentiviral plasmic backbone <sup><xref ref-type="bibr" rid="R29">29</xref></sup>. <italic>LIMD1</italic><sup>+/+</sup> and <italic>LIMD1</italic><sup>-/-</sup> cells expressing Cas9 were transduced at low multiplicity of infection to ensure each cell received a single sgRNA. Screens were performed in two biological replicates, and cells were harvested at early and late timepoints for negative selection analysis <sup><xref ref-type="bibr" rid="R30">30</xref></sup>. The relative abundance of each sgRNA was compared between genotypes to identify differential dependencies.</p></sec><sec id="S5"><title>siRNA transfection</title><p id="P13">The following siRNAs were purchased from Merck/Sigma-Aldrich: GPX4 (SASI_Hs02_00308687), GPX4_2 (SASI_Hs01_00050315), PLK1 (SASI_Hs01_00194343), ACSL4 (SASI_Hs01_00114667), UBB (SASI_Hs01_00201423), and a non-targeting control (#SIC001). Additionally, ON-TARGETplus SMARTpool siRNAs targeting GPX4 (L-011676-00-0005) and corresponding non-targeting controls (D-001810-10-05) were obtained from Dharmacon reagents. siRNAs were transfected using DharmaFECT 1 (Horizon Discovery) and Opti-MEM (ThermoFisher) according to manufacturer’s protocol.</p></sec><sec id="S6"><title>Western blotting</title><p id="P14">Cells were lysed in RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, supplemented with protease inhibitors (Roche, #04906837001) and phosphatase inhibitors (ThermoFisher, #A32955). Protein concentration was quantified using the BCA assay (ThermoFisher, #23225). Samples (20-30 µg) were prepared in 5x SDS loading buffer, boiled at 95 °C for 5 minutes, and resolved on 12% Bis-Tris or Tris-Glycine gels. Proteins were transferred onto PVDF membranes (Sigma, #IPVH00010), blocked, and probed with the following primary antibodies: LIMD1 (1:2000; in-house), LIMD1 (1:1000; Cell Signaling #13245), GPX4 (1:1000; Cell Signaling #52455S), and β-actin (1:20000 dilution; Sigma #A5441). HRP-conjugated secondary antibodies (Agilent) were used for detection via enhanced chemiluminescence (ThermoFisher #32106; Merck #WBKLS0500). Densitometry was performed using ImageJ 1.53e (NIH), and protein levels were normalised to β-actin or vinculin, from the same membrane.</p></sec><sec id="S7"><title>Cell viability assay (CellTiter-Glo)</title><p id="P15">Cells were seeded in 96-well plates and either transfected with siRNA or treated 24 hours with a dose range of test compounds or vehicle. A549 cells received two treatments, RSL3 or erastin, 48 hours apart. H1299 and SAECs received a single 24-hour treatment. At endpoint, cell viability was measured using the CellTiter-Glo 2.0 assay (Promega, #G9241), diluted 1:4 with PBS. 100 µL of reagent was added per well, plates were shaken for 10 minutes at room temperature, and luminescence was measured after transferring 80 µL were transferred to white 96-well plates.</p></sec><sec id="S8"><title>Crystal violet colony formation assay</title><p id="P16">Cells were seeded in 6-well plates and treated 24 hours later with drugs or siRNA (reverse transfection). Media were refreshed every 2 – 3 days. Ten days post-treatment, cells were fixed with methanol and stained with 0.05% crystal violet. Colony intensity was quantified using ImageJ.</p></sec><sec id="S9"><title>IncuCyte live cell imaging</title><p id="P17">Cells were seeded into 96-well plates at an optimised density and either reverse-transfected with siRNA or treated with drug/vehicle 24 hours later. Plates were imaged every 3 hours using the IncuCyte ZOOM system (Essen Bioscience) at 10x magnification. Confluence was quantified using IncuCyte ZOOM software.</p></sec><sec id="S10"><title>Flow cytometry</title><p id="P18">Cells (1.25x10<sup>5</sup> cells per well) were seeded in 6-well plates, treated for 24 hours with drug or vehicle, and then stained for ROS and lipid peroxidation. Positive controls were treated with 300 µM H<sub>2</sub>O<sub>2</sub> (lipid peroxidation) or 100 µM TBHP (ROS) for 15 – 20 minutes. Cells were trypsinised, neutralised with 2% FBS in PBS (FACS buffer), pelleted, and resuspended in 500 µL FACS buffer containing either 2 µM BODIPY 581/591 C11 (ThermoFisher #D3861) or 100 µM H2DCFDA (Tocris #5935). Cells were incubated for 15 minutes at 37 °C in the dark, washed twice, and passed through a 35 µm strainer polystyrene tubes (Corning #352235). A minimum of 10,000 events were collected per sample using a BD LSR Fortessa cytometer (FITC 488 nm and PE 582 nm lasers), and data were analysed in FlowJo v10 using appropriate gating.</p></sec><sec id="S11"><title>Oil Red O staining</title><p id="P19">Isogenic H1299 cells were seeded onto coverslips in 6-well plates (1.25 x 10<sup>5</sup> cells per well). After 24 hours, cells were treated with 100 µM of BSA-oleate (Cayman #29557) or BSA control (Cayman #29556) for another 24 hours. Oil Red O working solution was prepared by mixing 6 mL of 5 mg/mL stock with 4 mL distilled water, incubating for 10 minutes, and filtering. Cells were fixed in 4% PFA for 15 minutes on ice, washed in PBS, incubated with 60% isopropanol for 5 minutes, then stained with Oil Red O for 15 minutes. After rinsing, cells were counterstained with haematoxylin (Vector H-3502), followed by a bluing agent. Coverslips were mounted using Vectashield (Vector H-1000) and imaged on a Zeiss microscope.</p></sec><sec id="S12"><title>Statistical analysis</title><p id="P20">GraphPad Prism, v9.4.0 was used for all statistical analyses. Data were normalised to relevant controls. Appropriate tests were selected based on group number and data. Dunnett’s multiple comparisons test was used for comparisons against a single control. Significance thresholds were defined as follows: *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.005, ****p &lt; 0.0001.</p></sec></sec><sec id="S13" sec-type="results"><title>Results</title><sec id="S14"><title>CRISPR-Cas9 screens identify GPX4 as a synthetic vulnerability in <italic>LIMD1</italic>-deficient lung cancer cells</title><p id="P21">To uncover novel synthetic dependencies arising from <italic>LIMD1</italic> loss, we performed whole-genome CRISPR-Cas9 dropout screens in isogenic A549 LUAD cells (<italic>LIMD1</italic><sup><italic>+/+</italic></sup> and <italic>LIMD1</italic><sup>-/-</sup>), using a pooled sgRNA library targeting 18,010 human genes (90,709 guides; <xref ref-type="fig" rid="F1">Fig. 1A</xref>), with cells harvested at early and late timepoints. Analysis of sgRNA abundance revealed distinct vulnerabilities between genotypes: <italic>LIMD1</italic>-proficient cells were enriched for dependencies in oxidative phosphorylation and the TCA cycle, including NDUFA1, NDUFA6, NDUFA8, NDUFC2, NDUFV1, ACAD9, FOXRED1, UQCR10, COA7, COX18, and SCO2 (<xref ref-type="fig" rid="F1">Fig. 1B, C</xref>). In contrast, <italic>LIMD1</italic>-deficient cells displayed significant enrichment for genes involved in selenocysteine (Sec) tRNA biosynthesis and incorporation pathway, including EEFSEC, SEPSECS, and PSTK. Notably, the sole Sec-containing enzyme among the enriched hits was glutathione peroxidase 4 (GPX4) – a selenoprotein that suppresses ferroptosis by detoxifying lipid hydroperoxides in cellular membranes <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>.</p><p id="P22">Ferroptosis, first described by Dixon et al. in 2012, is an iron-dependent form of regulated cell death driven by lipid peroxidation of polyunsaturated fatty acid (PUFA)-containing phospholipids <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>. GPX4 is a key ferroptosis defence enzyme and has emerged as a therapeutic target in multiple cancers, including NSCLC <sup><xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R33">33</xref></sup>.</p></sec><sec id="S15"><title><italic>GPX4</italic> silencing via RNAi selectively impairs viability of <italic>LIMD1</italic>-deficient LUAD and SAEC cells</title><p id="P23">To validate <italic>GPX4</italic> dependency, we used siRNAs targeting <italic>GPX4</italic> in A549 isogenic clones. Colony formation assays revealed that <italic>LIMD1</italic><sup>-/-</sup> clones (C5, C10) exhibited significantly impaired clonogenic potential compared to the <italic>LIMD1</italic><sup><italic>+/+</italic></sup> (C3) upon <italic>GPX4</italic> knockdown (<xref ref-type="fig" rid="F2">Fig. 2A–C</xref>). Similar results were obtained in H1299 LUAD isogenic lines using two independent siRNA sequences. Live cell imaging showed that both <italic>LIMD1</italic><sup>-/-</sup> clones (C25, C59) exhibited decreased confluence upon <italic>GPX4</italic> knockdown compared to <italic>LIMD1</italic><sup><italic>+/+</italic></sup> clones (C8, C9), while PLK1 siRNA served as a positive control for cytotoxicity (<xref ref-type="fig" rid="F2">Fig. 2D, E</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S1A, B</xref>). Cell viability assays confirmed this genotype-selective effect (<xref ref-type="supplementary-material" rid="SD1">Fig. S1C</xref>).</p><p id="P24">To extend these findings to a non-transformed background to exclude cooperation between <italic>LIMD1</italic> loss and other oncogenic drivers, we used isogenic primary human SAECs. SMARTpool siRNA-mediated <italic>GPX4</italic> knockdown in <italic>LIMD1</italic><sup>-/-</sup> SAECs (C2, C10) significantly decreased cell viability compared to <italic>LIMD1</italic><sup><italic>+/+</italic></sup> cells (C4), with ferrostatin-1 (Fer-1) rescuing this effect, confirming ferroptosis as the mode of cell death (<xref ref-type="fig" rid="F2">Fig. 2F, G</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S1D</xref>). Live cell imaging similarly revealed selective growth inhibition in <italic>LIMD1</italic><sup>-/-</sup> SAECs (<xref ref-type="supplementary-material" rid="SD1">Fig. S2E, F</xref>). Finally, cell membrane integrity assays confirmed cytotoxic (not merely cytostatic) effects of <italic>GPX4</italic> silencing in <italic>LIMD1</italic><sup>-/-</sup> SAECs (<xref ref-type="fig" rid="F2">Fig. 2H, I</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S2g</xref>). These results demonstrate that <italic>LIMD1</italic>-deficient LUAD and normal airway cells are selectively dependent on <italic>GPX4</italic> for survival, consistent with a synthetic lethal interaction.</p></sec><sec id="S16"><title>GPX4 inhibition using ferroptosis-inducing agents confirms enhanced sensitivity in <italic>LIMD1</italic>-deficient cells</title><p id="P25">To pharmacologically validate the dependency on <italic>GPX4</italic>, we treated isogenic A549, H1299, and SAECs with multiple ferroptosis inducing agents (FINs), including class I (erastin, IKE), class II (RSL3, ML210), and class III (FIN56) inhibitors <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup>. In A549 isogenic cells, RSL3 and erastin treatment selectively impaired viability of <italic>LIMD1</italic><sup>-/-</sup> cells, which was rescued by Fer-1 co-treatment (<xref ref-type="fig" rid="F3">Fig. 3A–D</xref>).</p><p id="P26">As standard DMEM and RPMI lack sodium selenite, required for selenocysteine incorporation and full GPX4 activity <sup><xref ref-type="bibr" rid="R37">37</xref></sup>, we validated our findings in Plasmax, a physiologically relevant medium containing 25 nM sodium selenite, <sup><xref ref-type="bibr" rid="R38">38</xref></sup>. In H1299 isogenic cells cultured in Plasmax, <italic>LIMD1</italic><sup>-/-</sup> cells showed increased sensitivity to RSL3, IKE and FIN56 (<xref ref-type="fig" rid="F3">Fig. 3E–G</xref>), all reversed by Fer-1 (<xref ref-type="fig" rid="F3">Fig. 3H</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S2A, B</xref>). Similar ferroptosis-specific sensitivity was observed in SAECs: ML210 and erastin selectively reduced the viability of <italic>LIMD1</italic><sup>-/-</sup> clones, with Fer-1 rescuing the effect (<xref ref-type="fig" rid="F3">Fig. 3K–N</xref>). Together, these data robustly validate GPX4 as a ferroptosis-specific vulnerability in <italic>LIMD1</italic>-deficient lung epithelial cells across transformed and primary models.</p></sec><sec id="S17"><title><italic>LIMD1</italic>-deficient cells exhibit a ferroptosis-prone basal state characterised by elevated lipid accumulation and oxidative stress</title><p id="P27">To understand the mechanisms underlying GPX4 dependence, we assessed key ferroptosis-enabling features. Phospholipid composition and oxidative stress are critical determinants of ferroptosis sensitivity: PUFA-rich membranes promote ferroptosis, while MUFAs are protective <sup><xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref></sup>. Oil Red O staining revealed elevated basal lipid droplet accumulation in <italic>LIMD1</italic><sup>-/-</sup> H1299 cells, further exacerbated by BSA-oleate treatment (<xref ref-type="fig" rid="F4">Fig. 4A, B</xref>), suggesting a differential lipid supply in <italic>LIMD1</italic> deficient cells.</p><p id="P28">We next assessed oxidative stress and lipid peroxidation using H2DCFDA and ratiometric C11 BODIPY (581/591) probes. <italic>LIMD1</italic><sup>-/-</sup> H1299 exhibited significantly elevated basal ROS and lipid peroxidation (<xref ref-type="fig" rid="F4">Fig. 4C, D</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S3A</xref>). Similar results were also obtained in the <italic>LIMD1</italic><sup>-/-</sup> SAECs, displaying significantly heightened basal ROS levels (<xref ref-type="fig" rid="F4">Fig. 4F</xref>). RSL3 or ML210 treatment further increased lipid peroxidation in a dose-dependent manner only in <italic>LIMD1</italic><sup>-/-</sup> cells, again reversed by Fer-1 (<xref ref-type="fig" rid="F4">Fig. 4E, H</xref>). Moreover, H<sub>2</sub>O<sub>2</sub> exposure induced disproportionately higher lipid peroxidation in <italic>LIMD1</italic><sup>-/-</sup> cells, reinforcing their hypersensitivity (<xref ref-type="fig" rid="F4">Fig. 4H</xref>). Reduced GSH:GSSG ratios in <italic>LIMD1</italic><sup>-/-</sup> cells confirmed elevated redox stress (<xref ref-type="supplementary-material" rid="SD1">Fig. S3B</xref>).</p><p id="P29">Collectively, these findings reveal a ferroptosis-prone state upon <italic>LIMD1</italic> loss, marked by increased lipid content, basal oxidative stress, and redox imbalance, providing mechanistic insight into the observed <italic>GPX4</italic> dependency.</p></sec></sec><sec id="S18" sec-type="discussion"><title>Discussion</title><sec id="S19"><title>GPX4 dependency reveals a synthetic vulnerability and therapeutic opportunity in <italic>LIMD1</italic>-deficient lung cancers</title><p id="P30">Lung cancer (LC) remains the most lethal cancer globally, with overall 5-year survival rates still dismal despite advanced in immunotherapy and targeted therapies. The urgent need for novel, biologically informed treatments in especially acute in non-small cell lung cancer (NSCLC), where tumour heterogeneity, late-stage diagnosis, and therapeutic resistance continue to undermine durable outcomes. Our study identifies and validates a critical vulnerability in <italic>LIMD1</italic>-deficient NSCLC–selective dependency on the selenoprotein glutathione peroxidase 4 (GPX4), offering a new therapeutic axis based on synthetic lethality.</p><p id="P31"><italic>LIMD1</italic> is frequently lost early in the pathogenesis on NSCLC, particularly in LUAD and LUSC subtypes. Loss of <italic>LIMD1</italic> occurs in a clonal fashion and correlates with reduced mRNA expression and poor patient prognosis <sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>. <italic>LIMD1</italic> deficiency dismantles multiple tumour suppressive circuits, but also presents a therapeutic challenge: no single downstream effector is easily druggable. Here, using unbiased CRISPR-Cas9 dropout screens in isogenic LUAD and primary airway epithelial cells, we uncover <italic>GPX4</italic> as a robust synthetic lethal partner in the context in <italic>LIMD1</italic> loss.</p><p id="P32">GPX4 plays a non-redundant role in detoxifying phospholipid hydroperoxides, safeguarding cells from ferroptosis <sup><xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. Our screens highlighted not only GPX4, but also components of the selenocysteine biosynthesis and incorporation pathway (EEFSEC, SEPSECS, PSTK), suggesting that <italic>LIMD1</italic>-deficient cells rely on a heightened ferroptosis defence program. We demonstrate that targeting GPX4 through siRNA or ferroptosis-inducing agents (FINs) such as RSL3, ML210, FIN56, and erastin, selectively kills <italic>LIMD1</italic>-deficient cells, both in LUAD lines and in primary SAECs. This synthetic lethality appears driven by a ferroptosis-sensitised basal state marked by elevated reactive oxygen species (ROS), enhanced lipid peroxidation, altered glutathione redox status, and increased lipid droplet accumulation.</p><p id="P33">This ferroptosis-prone metabolic rewiring has clear therapeutic implications. First, we show that <italic>LIMD1</italic>-deficient cells are selectively sensitive to three classes of FINs, underscoring the robustness of the <italic>GPX4</italic> dependency. Second, this sensitivity was retained in physiologically relevant media (Plasmax), supporting translational evidence. Third, rescue with the lipophilic antioxidant Fer-1 confirmed the observed cytotoxicity is ferroptosis-specific.</p><p id="P34">Importantly, our findings align with and extend previous reports linking GPX4 overexpression to poor outcomes in LUAD <sup><xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R43">43</xref></sup> and therapeutic resistance in NSCLC <sup><xref ref-type="bibr" rid="R43">43</xref>–<xref ref-type="bibr" rid="R47">47</xref></sup>. In particular, GPX4 inhibition has been shown to synergise with cisplatin <sup><xref ref-type="bibr" rid="R46">46</xref></sup>, reverse radiotherapy resistance <sup><xref ref-type="bibr" rid="R47">47</xref></sup>, and enhance the effects of immune checkpoint blockade <sup><xref ref-type="bibr" rid="R48">48</xref></sup>. This last point is especially notable: interferon-γ released by activated CD8<sup>+</sup> T-cells downregulates SLC7A11 via STAT1, depleting glutathione and indirectly suppressing GPX4 function. Thus, combining FINs with immunotherapies in <italic>LIMD1</italic>-deficient tumours may offer a compelling dual-attack strategy that exploits both ferroptotic and immunogenic vulnerabilities.</p><p id="P35">From a biological perspective, our results point to a mechanistic model in which <italic>LIMD1</italic>-deficient cells accumulate oxidative and lipid stress, relying on GPX4 as a key survival mechanism. We demonstrate increased basal ROS and lipid peroxidation, as well as dysregulated lipid metabolism, both critical preconditions for ferroptosis <sup><xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R49">49</xref></sup>. Notably, <italic>LIMD1</italic>-deficient cells also show enhanced lipid droplet formation and altered fatty acid composition, which could influence membrane vulnerability to peroxidation and ferroptotic commitment. These findings open the door to broader metabolic characterisation of <italic>LIMD1</italic>-deficient NSCLCs, including how PUFA uptake, incorporation, and organelle-specific redox homeostasis are rewired upon <italic>LIMD1</italic> loss.</p></sec><sec id="S20"><title>Future directions and translational outlook</title><p id="P36">To translate these findings into a therapeutic context, several next steps are essential. First, <italic>in vivo</italic> validation of <italic>GPX4</italic> dependency using FINs in LIMD1-deficient GEMM models and patient-derived xenografts will be critical to assess therapeutic efficacy and toxicity profiles. Second, lipidomic and metabolomic analyses will clarify which specific lipid classes and unsaturation profiles drive ferroptosis susceptibility in <italic>LIMD1</italic>-deficient cells. Third, high-resolution and organelle-specific imaging will help define where ROS and lipid peroxidation events initiate upon <italic>LIMD1</italic> loss and FIN challenge. Finally, understanding how LIMD1 interacts with the immune microenvironment may reveal further opportunities to combine ferroptosis inducers with immunotherapies or redox modulators.</p></sec></sec><sec id="S21" sec-type="conclusions"><title>Conclusions</title><p id="P37">In sum, our study establishes GPX4 as a novel, actionable synthetic lethality in <italic>LIMD1</italic>-deficient NSCLC, revealing a ferroptosis-sensitive metabolic state that can be therapeutically exploited. By demonstrating selective GPX4 dependency across LUAD lines and primary epithelial models, and across multiple classes of FINs, we identify a tractable vulnerability with potential for personalised treatment strategies. As <italic>LIMD1</italic> loss occurs early and clonally in NSCLC evolution, targeting this axis may enable both early intervention and long-term disease control. These findings open new avenues for patient stratification and therapeutic design in one of the most challenging cancer types, and pave the way for clinical efforts to improve lung cancer outcomes through ferroptosis-based precision medicine.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS206281-suppement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d23aAcFbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Acknowledgements</title><p>We acknowledge the technical assistance provided by the BCI Flow Cytometry and Microscopy Core Facilities. We thank the Cancer Research UK-AstraZeneca Functional Genomics Centre for conducting the CRISPR-Cas9 dropout screens.</p><sec id="S23"><title>Funding</title><p>This study was supported by funding from Barts Charity (G-002509) and Cancer Research UK (C355/A25137); also Biotechnology and Biological Sciences Research Council (Swindon, GB); (BB/V009567/1), awarded to Tyson V. Sharp (TVS). Additional support was provided by The CRUK City of London Major Centre Awards (C7893/A26233 and CTRQQR-2021\100004).</p></sec></ack><fn-group><fn fn-type="conflict" id="FN1"><p id="P38"><bold>Conflict of interest</bold></p><p id="P39">B.R.S. is an inventor on patents and patent applications involving ferroptosis; co-founded and serves as a consultant to ProJenX, Inc. and Exarta Therapeutics; holds equity in Sonata Therapeutics; serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer&amp; Feld LLP. The remaining authors declare no competing interests.</p></fn><fn fn-type="conflict" id="FN2"><p id="P40"><bold>Conflict of Interest:</bold> The authors declare no conflict of interest exist.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thandra</surname><given-names>KC</given-names></name><name><surname>Barsouk</surname><given-names>A</given-names></name><name><surname>Saginala</surname><given-names>K</given-names></name><name><surname>Aluru</surname><given-names>JS</given-names></name><name><surname>Barsouk</surname><given-names>A</given-names></name></person-group><article-title>Epidemiology of lung cancer</article-title><source>Contemp Oncol (Pozn)</source><year>2021</year><volume>25</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmcid">PMC8063897</pub-id><pub-id pub-id-type="pmid">33911981</pub-id><pub-id pub-id-type="doi">10.5114/wo.2021.103829</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="web"><collab>CRUK</collab><source>Lung cancer statistics</source><comment>&lt;<ext-link ext-link-type="uri" xlink:href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer#:~:text=Lung%20cancer%20incidence,cases%20(2016%2D2018)">https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer#:~:text=Lung%20cancer%20incidence,cases%20(2016%2D2018)</ext-link>&gt;</comment></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>T</given-names></name><name><surname>Dy</surname><given-names>GK</given-names></name><name><surname>Adjei</surname><given-names>AA</given-names></name></person-group><article-title>Small cell lung cancer</article-title><source>Mayo Clin Proc</source><year>2008</year><volume>83</volume><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">18316005</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zappa</surname><given-names>C</given-names></name><name><surname>Mousa</surname><given-names>SA</given-names></name></person-group><article-title>Non-small cell lung cancer: current treatment and future advances</article-title><source>Transl Lung Cancer Res</source><year>2016</year><volume>5</volume><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="pmcid">PMC4931124</pub-id><pub-id pub-id-type="pmid">27413711</pub-id><pub-id pub-id-type="doi">10.21037/tlcr.2016.06.07</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name></person-group><article-title>Epidemiology of lung cancer prognosis: quantity and quality of life</article-title><source>Methods Mol Biol</source><year>2009</year><volume>471</volume><fpage>469</fpage><lpage>486</lpage><pub-id pub-id-type="pmcid">PMC2941142</pub-id><pub-id pub-id-type="pmid">19109795</pub-id><pub-id pub-id-type="doi">10.1007/978-1-59745-416-2_24</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nesbitt</surname><given-names>JC</given-names></name><name><surname>Putnam</surname><given-names>JB</given-names><suffix>Jr</suffix></name><name><surname>Walsh</surname><given-names>GL</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Mountain</surname><given-names>CF</given-names></name></person-group><article-title>Survival in early-stage non-small cell lung cancer</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>60</volume><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">7646126</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrella</surname><given-names>F</given-names></name><etal/></person-group><article-title>Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options</article-title><source>Curr Oncol</source><year>2023</year><volume>30</volume><fpage>3160</fpage><lpage>3175</lpage><pub-id pub-id-type="pmcid">PMC10047909</pub-id><pub-id pub-id-type="pmid">36975452</pub-id><pub-id pub-id-type="doi">10.3390/curroncol30030239</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schad</surname><given-names>F</given-names></name><etal/></person-group><article-title>Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><elocation-id>e0203058</elocation-id><pub-id pub-id-type="pmcid">PMC6110500</pub-id><pub-id pub-id-type="pmid">30148853</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0203058</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polanco</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study</article-title><source>J Thorac Dis</source><year>2021</year><volume>13</volume><fpage>1485</fpage><lpage>1494</lpage><pub-id pub-id-type="pmcid">PMC8024804</pub-id><pub-id pub-id-type="pmid">33841941</pub-id><pub-id pub-id-type="doi">10.21037/jtd-20-3075</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Boshoff</surname><given-names>C</given-names></name></person-group><article-title>The biology and management of non-small cell lung cancer</article-title><source>Nature</source><year>2018</year><volume>553</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">29364287</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Qiao</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><article-title>The cutting-edge progress of immune-checkpoint blockade in lung cancer</article-title><source>Cell Mol Immunol</source><year>2021</year><volume>18</volume><fpage>279</fpage><lpage>293</lpage><pub-id pub-id-type="pmcid">PMC8027847</pub-id><pub-id pub-id-type="pmid">33177696</pub-id><pub-id pub-id-type="doi">10.1038/s41423-020-00577-5</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>TV</given-names></name><etal/></person-group><article-title>The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>19932</fpage><lpage>19937</lpage><pub-id pub-id-type="pmcid">PMC2604919</pub-id><pub-id pub-id-type="pmid">19060205</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0805003105</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foxler</surname><given-names>DE</given-names></name><etal/></person-group><article-title>PU.1 is a major transcriptional activator of the tumour suppressor gene LIMD1</article-title><source>FEBS Lett</source><year>2011</year><volume>585</volume><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="pmcid">PMC3078326</pub-id><pub-id pub-id-type="pmid">21402070</pub-id><pub-id pub-id-type="doi">10.1016/j.febslet.2011.03.013</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petursdottir</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues</article-title><source>Genes Chromosomes Cancer</source><year>2004</year><volume>41</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">15334546</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggins</surname><given-names>CJ</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name></person-group><article-title>Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers</article-title><source>Cancer Letters</source><year>2008</year><volume>267</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">18439753</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foxler</surname><given-names>DE</given-names></name><etal/></person-group><article-title>A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia</article-title><source>EMBO Mol Med</source><year>2018</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC6079541</pub-id><pub-id pub-id-type="pmid">29930174</pub-id><pub-id pub-id-type="doi">10.15252/emmm.201708304</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>KM</given-names></name><etal/></person-group><article-title>LIMD1 Loss as an Early Driver of PD-L1 Upregulation and Immune Evasion in Lung Cancer</article-title><source>bioRxiv</source><year>2025</year><elocation-id>2025.2002.2006.636805</elocation-id><pub-id pub-id-type="doi">10.1101/2025.02.06.636805</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>TV</given-names></name><etal/></person-group><article-title>LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>16531</fpage><lpage>16536</lpage><pub-id pub-id-type="pmcid">PMC534532</pub-id><pub-id pub-id-type="pmid">15542589</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0407123101</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadrmas</surname><given-names>JL</given-names></name><name><surname>Beckerle</surname><given-names>MC</given-names></name></person-group><article-title>The LIM domain: from the cytoskeleton to the nucleus</article-title><source>Nature Reviews Molecular Cell Biology</source><year>2004</year><volume>5</volume><fpage>920</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">15520811</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><fpage>1075</fpage><pub-id pub-id-type="pmcid">PMC8586256</pub-id><pub-id pub-id-type="pmid">34764236</pub-id><pub-id pub-id-type="doi">10.1038/s41419-021-04355-7</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foxler</surname><given-names>DE</given-names></name><etal/></person-group><article-title>The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity</article-title><source>Nat Cell Biol</source><year>2012</year><volume>14</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">22286099</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridge</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Argonaute Utilization for miRNA Silencing Is Determined by Phosphorylation-Dependent Recruitment of LIM-Domain-Containing Proteins</article-title><source>Cell Rep</source><year>2017</year><volume>20</volume><fpage>173</fpage><lpage>187</lpage><pub-id pub-id-type="pmcid">PMC5507773</pub-id><pub-id pub-id-type="pmid">28683311</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.027</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>V</given-names></name><etal/></person-group><article-title>LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-mediated gene silencing</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>12499</fpage><lpage>12504</lpage><pub-id pub-id-type="pmcid">PMC2906597</pub-id><pub-id pub-id-type="pmid">20616046</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0914987107</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Neil</surname><given-names>NJ</given-names></name><name><surname>Bailey</surname><given-names>ML</given-names></name><name><surname>Hieter</surname><given-names>P</given-names></name></person-group><article-title>Synthetic lethality and cancer</article-title><source>Nat Rev Genet</source><year>2017</year><volume>18</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">28649135</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topatana</surname><given-names>W</given-names></name><etal/></person-group><article-title>Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation</article-title><source>J Hematol Oncol</source><year>2020</year><volume>13</volume><fpage>118</fpage><pub-id pub-id-type="pmcid">PMC7470446</pub-id><pub-id pub-id-type="pmid">32883316</pub-id><pub-id pub-id-type="doi">10.1186/s13045-020-00956-5</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>1060</fpage><lpage>1072</lpage><pub-id pub-id-type="pmcid">PMC3367386</pub-id><pub-id pub-id-type="pmid">22632970</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><fpage>E4966</fpage><lpage>4975</lpage><pub-id pub-id-type="pmcid">PMC5003261</pub-id><pub-id pub-id-type="pmid">27506793</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1603244113</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockwell</surname><given-names>BR</given-names></name></person-group><article-title>Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2401</fpage><lpage>2421</lpage><pub-id pub-id-type="pmcid">PMC9273022</pub-id><pub-id pub-id-type="pmid">35803244</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.06.003</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzelepis</surname><given-names>K</given-names></name><etal/></person-group><article-title>A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia</article-title><source>Cell Rep</source><year>2016</year><volume>17</volume><fpage>1193</fpage><lpage>1205</lpage><pub-id pub-id-type="pmcid">PMC5081405</pub-id><pub-id pub-id-type="pmid">27760321</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.079</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><article-title>High-throughput functional genomics using CRISPR-Cas9</article-title><source>Nat Rev Genet</source><year>2015</year><volume>16</volume><fpage>299</fpage><lpage>311</lpage><pub-id pub-id-type="pmcid">PMC4503232</pub-id><pub-id pub-id-type="pmid">25854182</pub-id><pub-id pub-id-type="doi">10.1038/nrg3899</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Berghe</surname><given-names>TV</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>The molecular machinery of regulated cell death</article-title><source>Cell Research</source><year>2019</year><volume>29</volume><fpage>347</fpage><lpage>364</lpage><pub-id pub-id-type="pmcid">PMC6796845</pub-id><pub-id pub-id-type="pmid">30948788</pub-id><pub-id pub-id-type="doi">10.1038/s41422-019-0164-5</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>SJ</given-names></name><name><surname>Olzmann</surname><given-names>JA</given-names></name></person-group><article-title>The cell biology of ferroptosis</article-title><source>Nat Rev Mol Cell Biol</source><year>2024</year><pub-id pub-id-type="pmid">38366038</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>N</given-names></name><etal/></person-group><article-title>Ferroptosis in lung cancer: a novel pathway regulating cell death and a promising target for drug therapy</article-title><source>Cell Death Discovery</source><year>2023</year><volume>9</volume><fpage>110</fpage><pub-id pub-id-type="pmcid">PMC10067943</pub-id><pub-id pub-id-type="pmid">37005430</pub-id><pub-id pub-id-type="doi">10.1038/s41420-023-01407-z</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaton</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles</article-title><source>Nat Chem Biol</source><year>2020</year><volume>16</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmcid">PMC7251976</pub-id><pub-id pub-id-type="pmid">32231343</pub-id><pub-id pub-id-type="doi">10.1038/s41589-020-0501-5</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model</article-title><source>Cell Chem Biol</source><year>2019</year><volume>26</volume><fpage>623</fpage><lpage>633</lpage><elocation-id>e629</elocation-id><pub-id pub-id-type="pmcid">PMC6525071</pub-id><pub-id pub-id-type="pmid">30799221</pub-id><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.01.008</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis</article-title><source>Nat Chem Biol</source><year>2016</year><volume>12</volume><fpage>497</fpage><lpage>503</lpage><pub-id pub-id-type="pmcid">PMC4920070</pub-id><pub-id pub-id-type="pmid">27159577</pub-id><pub-id pub-id-type="doi">10.1038/nchembio.2079</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingold</surname><given-names>I</given-names></name><etal/></person-group><article-title>Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>409</fpage><lpage>422</lpage><elocation-id>e421</elocation-id><pub-id pub-id-type="pmid">29290465</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vande Voorde</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improving the metabolic fidelity of cancer models with a physiological cell culture medium</article-title><source>Sci Adv</source><year>2019</year><volume>5</volume><elocation-id>eaau7314</elocation-id><pub-id pub-id-type="pmcid">PMC6314821</pub-id><pub-id pub-id-type="pmid">30613774</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.aau7314</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magtanong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State</article-title><source>Cell Chem Biol</source><year>2019</year><volume>26</volume><fpage>420</fpage><lpage>432</lpage><elocation-id>e429</elocation-id><pub-id pub-id-type="pmcid">PMC6430697</pub-id><pub-id pub-id-type="pmid">30686757</pub-id><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.11.016</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>1177</fpage><lpage>1190</lpage><elocation-id>e1118</elocation-id><pub-id pub-id-type="pmcid">PMC10940216</pub-id><pub-id pub-id-type="pmid">38366593</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2024.01.030</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokol</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Lipid availability influences ferroptosis sensitivity in cancer cells by regulating polyunsaturated fatty acid trafficking</article-title><source>Cell Chem Biol</source><year>2025</year><volume>32</volume><fpage>408</fpage><lpage>422</lpage><elocation-id>e406</elocation-id><pub-id pub-id-type="pmcid">PMC11928283</pub-id><pub-id pub-id-type="pmid">39442523</pub-id><pub-id pub-id-type="doi">10.1016/j.chembiol.2024.09.008</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Glutathione peroxidase 4 expression predicts poor overall survival in patients with resected lung adenocarcinoma</article-title><source>Scientific Reports</source><year>2022</year><volume>12</volume><elocation-id>20462</elocation-id><pub-id pub-id-type="pmcid">PMC9705709</pub-id><pub-id pub-id-type="pmid">36443446</pub-id><pub-id pub-id-type="doi">10.1038/s41598-022-25019-2</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance</article-title><source>Transl Lung Cancer Res</source><year>2022</year><volume>11</volume><fpage>786</fpage><lpage>801</lpage><pub-id pub-id-type="pmcid">PMC9186177</pub-id><pub-id pub-id-type="pmid">35693278</pub-id><pub-id pub-id-type="doi">10.21037/tlcr-22-318</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>CS</given-names></name><etal/></person-group><article-title>NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells</article-title><source>Acta Pharmacol Sin</source><year>2021</year><volume>42</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="pmcid">PMC8115089</pub-id><pub-id pub-id-type="pmid">32704041</pub-id><pub-id pub-id-type="doi">10.1038/s41401-020-0443-1</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>567</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">34157442</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin</article-title><source>J Cell Physiol</source><year>2020</year><volume>235</volume><fpage>3425</fpage><lpage>3437</lpage><pub-id pub-id-type="pmid">31556117</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis</article-title><source>Oncol Lett</source><year>2019</year><volume>17</volume><fpage>3001</fpage><lpage>3008</lpage><pub-id pub-id-type="pmcid">PMC6365906</pub-id><pub-id pub-id-type="pmid">30854078</pub-id><pub-id pub-id-type="doi">10.3892/ol.2019.9888</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy</article-title><source>Nature</source><year>2019</year><volume>569</volume><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="pmcid">PMC6533917</pub-id><pub-id pub-id-type="pmid">31043744</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-1170-y</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Muñoz</surname><given-names>MF</given-names></name><name><surname>Argüelles</surname><given-names>S</given-names></name></person-group><article-title>Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal</article-title><source>Oxid Med Cell Longev</source><year>2014</year><volume>2014</volume><elocation-id>360438</elocation-id><pub-id pub-id-type="pmcid">PMC4066722</pub-id><pub-id pub-id-type="pmid">24999379</pub-id><pub-id pub-id-type="doi">10.1155/2014/360438</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>CRISPR-Cas9 dropout screens reveal dependency on selenoprotein GPX4 and enzymes involved in Sec-tRNA biosynthesis and incorporation.</title><p><bold>(A)</bold> CRISPR-Cas9 dropout screens performed in CRISPR-Cas9 generated isogenic A549 cells using a sgRNA library of 90,709 sequences targeting 18,010 human genes with a coverage of 5 sgRNAs per gene. <bold>(B)</bold> Dot-plot showing essential genes in <italic>LIMD1</italic><sup>-/-</sup> (green) and <italic>LIMD1</italic><sup><italic>+/+</italic></sup> cells (red) upon sgRNA abundance analysis following screen performed at an early time-point (10 days) and late time-point (17 days). <bold>(C-D)</bold> Schematic diagram revealing enzymes involved in ETC as essential vulnerabilities in <italic>LIMD1</italic><sup><italic>+/+</italic></sup> <bold>(C)</bold> whereas enzymes involved in Sec t-RNA biosynthesis and incorporation along with GPX4 are essential in <italic>LIMD1</italic><sup>-/-</sup> A549 cells <bold>(D)</bold>.</p></caption><graphic xlink:href="EMS206281-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>RNA interference-mediated <italic>GPX4</italic> targeting selectively inhibits <italic>LIMD1</italic>-deficient cells.</title><p><bold>(A)</bold> Immunoblot of isogenic A549 cells upon upon 30 nM siRNA treatment for 48 h. <bold>(B)</bold> Representative images from colony formation assay of isogenic A549 cells, seeded at 500 cells per well, upon treatment with 30 nM siRNA for 10 days, with growth medium being replenished every 2-3 days. <bold>(C)</bold> Integrated density quantification of colony formation assay images, shown as fold-change values normalised to the siSCR group for each cell line (n=3). <bold>(D)</bold> Immunoblot of isogenic H1299 cells upon upon 30 nM siRNA treatment for 48 h. <bold>(E)</bold> Phase object confluence levels of isogenic H1299 cells, seeded at 500 cells per well, upon 83 h reverse-transfection with 30 nM siRNA (n=3). <bold>(F)</bold> Immunoblot of isogenic SAEC cells upon upon 30 nM siRNA treatment for 48 h. <bold>(G)</bold> Surviving fractions of isogenic SAEC cells, seeded at 2000 cells per well, upon 96 h reverse-transfection with 30 nM siRNA (n=3). <bold>(H, I)</bold> Cell cytotoxicity levels <bold>(H)</bold> and associated-representative images <bold>(I)</bold> of isogenic SAEC cells, seeded at 2000 cells per well, upon 90 h reverse transfection with 30 nM siRNA (n=3). Data is shown as biological replicates ± S.E.M. Two-way ANOVA with Dunnett’s multiple comparisons test was performed in <bold>C, G</bold> and <bold>H</bold>, whereas Two-way ANOVA with Tukey’s comparisons test was performed in <bold>E</bold>. *<italic>p</italic> ≤ 0.05, **<italic>p</italic> ≤ 0.01, ***<italic>p</italic> ≤ 0.001, ****<italic>p</italic> ≤ 0.0001.</p></caption><graphic xlink:href="EMS206281-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>GPX4 targeting via ferroptosis inducing agents selectively inhibits <italic>LIMD1</italic>-deficient cells.</title><p><bold>(A, B)</bold> Dose-response curves showing surviving fractions of isogenic A549 cells upon RSL3 (n=4) <bold>(A)</bold> and erastin (n=2) treatment <bold>(B)</bold>, seeded at 1000 cells per well with a double dose of drug for 48 h followed by 48 h treatment. <bold>(C)</bold> Surviving fractions of isogenic A549 cells, seeded at 1000 cells per well, upon double dose of treatment of 48 followed by 48 h with DMSO, fer-1 (2 μM), RSL3 (2 μM), and RSL3 (2 μM) in combination with fer-1 (2 μM) (n=3). <bold>(D)</bold> Surviving fractions of isogenic A549 cells, seeded at 1000 cells per well, upon double dose of treatment of 48 followed by 48 h with DMSO, fer-1 (2 μM), erastin (5 μM), and erastin (5 μM) in combination with fer-1 (2 μM) (n=3). <bold>(E-G)</bold> Dose-response curves showing surviving fractions of isogenic H1299 cells grown in plasmax upon RSL3 <bold>(E)</bold>, IKE <bold>(F)</bold> and FIN56 <bold>(G)</bold> treatment for 24 h, seeded at 2000 cells per well (n=3). <bold>(H)</bold> Surviving fractions of isogenic H1299 grown in plasmax, upon 24 h treatment with DMSO, fer-1 (2 μM), RSL3 (8 nM) and RSL3 (8 nM) combined with fer-1(2 μM) (n=3). <bold>(I, J)</bold> Dose-response curves showing surviving fractions of isogenic SAEC cells upon ML210 <bold>(I)</bold> and erastin <bold>(J)</bold> treatment for 24 h, seeded at 3000 cells per well (n=3). <bold>(K)</bold> Surviving fractions of isogenic SAEC cells, upon 24 h treatment with DMSO, fer-1 (2 μM), ML210 (0.3 μM) and ML210 (0.3 μM) in combination with fer-1 (2 μM) (n=3). <bold>(L)</bold> Surviving fractions of isogenic SAEC cells, upon 24 h treatment with DMSO, fer-1 (2 μM), erastin (0.3 μM) and erastin (0.3 μM) in combination with fer-1 (2 μM) (n=3). Data is shown as biological replicates ± S.E.M. Two-way ANOVA with Dunnett’s multiple comparisons test was performed in <bold>A-D, I-L</bold>, whereas two-way ANOVA with Tukey’s comparisons test was performed in <bold>E-H</bold>, comparing mean values of C25 <italic>LIMD1</italic><sup>-/-</sup> and C59 <italic>LIMD1</italic><sup>-/-</sup> groups to both C8 <italic>LIMD1</italic><sup><italic>+/+</italic></sup>, shown by black asterisk, and C9 <italic>LIMD1</italic><sup><italic>+/+</italic></sup> groups, shown by purple asterisk. *<italic>p</italic> ≤ 0.05, **<italic>p</italic> ≤ 0.01, ***<italic>p</italic> ≤ 0.001, ****<italic>p</italic> ≤ 0.0001.</p></caption><graphic xlink:href="EMS206281-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title><italic>LIMD1</italic>-deficient cells exhibit higher levels of lipid droplets, ROS and lipid peroxidation.</title><p><bold>(A)</bold> Representative images of isogenic H1299 cells stained for lipid droplets with Oil Red O upon 24 h treatment with vehicle and BSA-conjugated Oleate (100 µM) (n=3). <bold>(B)</bold> Quantification of basal lipid droplet levels in isogenic H1299 cells. <bold>(C)</bold> ROS levels evaluated by H2DCFDA staining in isogenic H1299 cells following seeding in 6-well plates at a confluency of 1.25x10<sup>6</sup> cells per well (n=3). <bold>(D, E)</bold> Lipid peroxidation levels evaluated by C11-BODIPY 581/591 staining in isogenic H1299 cells under basal conditions (n=4) <bold>(D)</bold> and upon treatment <bold>(E)</bold> with RSL3 (8 nM, 10 nM, 20 nM), fer-1 (2 μM) and RSL3 (20 nM) combined with fer-1 (2 μM) for 24 h (n=3). <bold>(F)</bold> ROS levels evaluated by H2DCFDA staining in isogenic SAEC cells following seeding in 6-well plates at a confluency of 1.25x10<sup>6</sup> cells per well (n=3). <bold>(G, H)</bold> Lipid peroxidation levels evaluated by C11-BODIPY 581/591 staining in isogenic SAEC cells under basal conditions (n=4) <bold>(G)</bold> and upon treatment <bold>(H)</bold> with ML210 (0.1 µM, 0.2 µM), fer-1 (2 μM) for 24 h; H<sub>2</sub>O<sub>2</sub> (300 μM) and H<sub>2</sub>O<sub>2</sub> (300 μM) with fer-1 (2 μM) treatment was performed for the last 30 minutes (n=3). Data is shown as biological replicates ± S.D. in <bold>C-H</bold> and as biological replicates ± S.E.M. in <bold>B</bold>. One-way ANOVA with Dunnett’s multiple comparisons test was performed in <bold>B-D, F</bold>, whereas Two-way ANOVA with Bonferroni’s multiple comparisons test was performed in <bold>E</bold> and <bold>H</bold>. Two-tailed unpaired t-test was performed in <bold>G</bold>. *<italic>p</italic> ≤ 0.05, **<italic>p</italic> ≤ 0.01, ***<italic>p</italic> ≤ 0.001, ****<italic>p</italic> ≤ 0.0001.</p></caption><graphic xlink:href="EMS206281-f004"/></fig></floats-group></article>